BofA Securities Reiterates Underperform Rating on Lyell Immunopharma (LYEL), PT $12, 'we continue to view the story cautiously'
BofA Securities analyst Geoff Meacham reiterated an Underperform rating and $12.00 price target on Lyell Immunopharma (NASDAQ: LYEL)The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)